within Pharmacolibrary.Drugs.ATC.G;

model G01AF13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.001,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg â†’ kg
    adminCount     = 1,
    Vd             = 0.0007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0003333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G01AF13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Azanidazole is a nitroimidazole derivative that was developed as an antiprotozoal agent, particularly for the treatment of Chagas disease (American trypanosomiasis). It is structurally related to other nitroimidazoles but is not approved or marketed for current clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are not reported in the scientific literature for humans. Values below are estimates based on structurally similar nitroimidazoles (e.g., metronidazole) and expert assumptions.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G01AF13;
